the Effectiveness and Safety Study on PD-1 Combined With Pyrotinib for First-line Chemotherapy Failed HER2 Insertion Mutation Advanced Non-small Cell Lung Cancer
Who is this study for? Patients with first-line chemotherapy failed HER2 insertion mutation advanced non-small cell lung cancer
What treatments are being studied? PD-1+Pyrotinib
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to assess the safety and effectiveness of PD-1 Combined With Pyrotinib for First-line chemotherapy failed HER2 Insertion Mutation Positive Advanced Non-small Cell Lung Cancer
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Advanced non-small cell lung cancer confirmed by histology or cytology
• HER2 insertion mutation-positive
• Failure with first-line standard chemotherapy
• with measurable lesions.
Locations
Other Locations
China
Hunan Provincal Tumor Hospital
RECRUITING
Changsha
Contact Information
Primary
Yongchang Zhang, MD
zhangyongchang@csu.edu.cn
+8613873123436
Backup
Xiangyu Zhang, PhD
514775505@qq.com
Time Frame
Start Date: 2019-01-30
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 30
Treatments
Experimental: PD-1 Combined With Pyrotinib
PD-1 combined With pyrotinib used fo first-line chemotherapy failedr HER2 Insertion mutation positive advanced NSCLC
Related Therapeutic Areas
Sponsors
Leads: Yongchang Zhang